

Publications

Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers, Dhanusha Sabanathan, Douglas H. Campbell, Vicki M. Velonas, Sandra Wissmueller, Hubert Mazure, Marko Trifunovic, Pirooz Poursoltan, Kevin Ho Shon, Tiffany R. Mackay, Maria E. Lund, Yanling Lu, Paul J. Roach, Dale L. Bailey, Bradley J. Walsh, David Gillatt, Howard Gurney. Under review at EJNMMI Research.

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells, Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler, Bradley J. Walsh. BMC Cancer 2020, In press.

The feasibility of Miltuximab®-IRDye700DX-mediated photodynamic therapy of solid tumors, Dmitry M. Polikarpov, Douglas H. Campbell, Maria E. Lund, Yanling Lu, Yiqing Lu, Jiehua Wu, Bradley J. Walsh, Andrei V. Zvyagin, David A. Gillatt. Photodiagnosis and Photodynamic Therapy 2020, 15:102064 <https://doi.org/10.1016/j.pdpdt.2020.102064>

RetroSPECT – Gallium-67 as a Theranostic Imaging Agent, Dale L. Bailey, Dhanusha Sabanathan, Alireza Aslani, Douglas H. Campbell, Bradley J. Walsh, Nigel A. Lengkeek. Submitted to Asia Oceania Journal of Nuclear Medicine and Biology.

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery, Dmitry M. Polikarpov, Douglas H. Campbell, Lucinda S. McRobb, Jiehua Wu, Maria E. Lund, Yanling Lu, Sergey M. Deyev, Andrew S. Davidson, Bradley J. Walsh, Andrei V. Zvyagin and David A. Gillatt. Cancers 2020, 12(4): 984; <http://doi.org/10.3390/cancers12040984>

Targeted beta therapy of prostate cancer with ¹⁷⁷Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1), Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson and Pamela J. Russell. EJNMMI Research 2020, 10(1):46; <https://doi.org/10.1186/s13550-020-00637-x>

The Role of Glypican-1 in the Tumour Microenvironment, Maria E. Lund, Douglas H. Campbell and Bradley J. Walsh. Advances in Experimental Medicine and Biology 2020, 1245: 163-176; https://doi.org/10.1007/978-3-030-40146-7_8

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells, Dmitry Polikarpov, Luen Liang, Andrew Care, Anwar Sunna, Douglas Campbell, Bradley Walsh, Irina Balalaeva, Andrei Zvyagin, David Gillatt and Evgenii Guryev. Biomolecules 2019, 9(12): 820; <https://doi.org/10.3390/biom9120820>

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker, Rachel A. Levin, Maria E. Lund, Quach Truong, Angela Wu, Neal D. Shore, Daniel R. Saltzstein, Raoul S. Concepcion, Thomas A. Paivanas, Arletta van Breda, Jennifer Beebe-Dimmer, Julie J. Ruterbusch, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. Oncotarget 2018, 9(32): 22359–22367; <https://doi.org/10.18632/oncotarget.25009>

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer, Douglas H. Campbell, Maria E. Lund, Aline L. Nocon, Paul J. Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L. Beebe-Dimmer, Julie J. Ruterbusch, Bradley J. Walsh. PLoS ONE 2018, 13(4): e0196017; <https://doi.org/10.1371/journal.pone.0196017>

Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization, Quach Truong, Irene O. Justiniano, Aline L. Nocon, Julie T. Soon, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. J Cancer 2016, 7(8): 1002-1009; <https://doi.org/10.7150/jca.14645>